Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| ASCT0631D | COG | A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors with and without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631 | Pediatric CIRB | Completed | |
| ASCT1221 | COG | A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML) | Pediatric CIRB | Completed | |
| ASCT2031 | COG | A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS) | Pediatric CIRB | Available to Open | |
| B-31 dbGAP | NSABP | Comparison of methods for development of predictive signatures for therapy selection | Adult CIRB - Late Phase Emphasis | Available to Open | |
| C80405 | CALGB | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab; or Cetuximab (C225); or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-100104 | CALGB | A Phase III Randomized; Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813; IND#70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| CALGB-10201 | CALGB | A Phase III Study of Daunorubicin and Cytarabine +\- G3139 (GenasenseTM; Oblimersen Sodium; NSC #683428; IND #58842); A BCL2 Antisense Oligodeoxynucleotide; in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > 60 Years | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-10501 | CALGB | A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease <br> | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-10603 | CALGB | A Phase III Randomized; Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| CALGB-10701 | CALGB | A Phase II Study of Dasatinib (Sprycel) (IND #73969; NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB; ECOG and SWOG | Adult CIRB - Late Phase Emphasis | Completed |